Report on the Department of Health and Human Services--Public Health Service, Health Care Financing Administration /

Also known as: The Grace report.

Review of the Public Health Service's response to AIDS.

Item 1070-M.

Organization and staffing for local health services; analysis of information submitted to the Public Health Service in Report of public Health personnel as of January 1, 1958.

Mode of access: Internet.

Various authorizations to units of the national park system and an addition to the wild and scenic river system : hearing before the Subcommittee on Public Lands, Reserved Water, and Resource Conservation of the Committee on Energy and Natural Resources, United States Senate, Ninety-ninth Congress, second session ....

Shipping list no.: 86-432-P (pt. 2).

Miscellaneous conveyances, transfers, and boundary modifications pertaining to public lands : hearing before the Subcommittee on Public Lands, Reserved Water, and Resource Conservation of the Committee on Energy and Natural Resources, United States Senate, Ninety-ninth Congress, first session on S. 304, S. 829, S. 360, S. 1530, S. 446, S. 1625, S. 565, S. 1690, S. 567.

"March 4, 1986"--Pt. 2.

Superfund Reform Act of 1994 : hearings before the Subcommittee on Superfund, Recycling, and Solid Waste Management of the Committee on Environment and Public Works, United States Senate, One Hundred Third Congress, second session, on S. 1834, a bill to amend the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, and for other purposes, February 10; March 2; and April 12, 1994-< >

Shipping list no.: 94-0216-P.

Rio Chama River, New Mexico : hearing before the Subcommittee on Public Lands, National Parks, and Forests of the Committee on Energy and Natural Resources, United States Senate, One Hundredth Congress, first session on S. 850 to amend the Wild and Scenic Rivers Act to designate a segment of the Rio Chama River in New Mexico as a component of the National Wild and Scenic Rivers System.

"December 17, 1987"--Pt. 2.

Old age income assurance ; a compendium of papers on problems and policy issues in the public and private pension sytem, submitted to the Subcommittee on Fiscal Policy of the Joint Economic Committee /

At head of title: 90th Congress, 1st session. Joint committee print.

Public Health Personnel, Facilities, and Services in Local Areas, Analysis of Information Submitted to the Public Health Service in Report of Public Health Personnel, Facilities, and Services

Cover Title: Report of Local Public Health Resources

Proceedings of the Public Health Conference on Records and Statistics, 15th national meeting.

Mode of access: Internet.

Federal aid for education. Hearings before the Committee on education and labor, U. S. Senate, 79th Congress, 1st session, on S. 181, a bill to authorize the appropriation of funds to assist the states and territories in more adequately financing their systems of public education during emergency, and in reducing the inequalities of educational opportunities through public elementary and secondary schools...

James E. Murray, chairman.

Idaho wilderness : hearings before the Subcommittee on Public Lands and Reserved Water of the Committee on Energy and Natural Resources, United States Senate, Ninety-eighth Congress, first session, to review the Idaho wilderness recommendations.

"Coeur D'Alene, Idaho, August 16, 1983; Lewiston, Idaho, August 17, 1983"--Pt. 2.

Review of Health Impact Assessments in the Criminal Justice System, 2001-2016

Thesis (Master's)--University of Washington, 2016-06

Distribution of major health risks: findings from the global burden of disease study

Background Most analyses of risks to health focus on the total burden of their aggregate effects. The distribution of risk-factor-attributable disease burden, for example by age or exposure level, can inform the selection and targeting of specific interventions and programs, and increase cost-effectiveness. Methods and Findings For 26 selected risk factors, expert working groups conducted comprehensive reviews of data on risk-factor exposure and hazard for 14 epidemiological subregions of the world, by age and sex. Age-sex-subregion-population attributable fractions were estimated and applied to the mortality and burden of disease estimates from the World Health Organization Global Burden of Disease database. Where possible, exposure levels were assessed as continuous measures, or as multiple categories. The proportion of risk-factor-attributable burden in different population subgroups, defined by age, sex, and exposure level, was estimated. For major cardiovascular risk factors (blood pressure, cholesterol, tobacco use, fruit and vegetable intake, body mass index, and physical inactivity) 43%-61% of attributable disease burden occurred between the ages of 15 and 59 y, and 87% of alcohol-attributable burden occurred in this age group. Most of the disease burden for continuous risks occurred in those with only moderately raised levels, not among those with levels above commonly used cut-points, such as those with hypertension or obesity. Of all disease burden attributable to being underweight during childhood, 55% occurred among children 1-3 standard deviations below the reference population median, and the remainder occurred among severely malnourished children, who were three or more standard deviations below median. Conclusions Many major global risks are widely spread in a population, rather than restricted to a minority. Population-based strategies that seek to shift the whole distribution of risk factors often have the potential to produce substantial reductions in disease burden.

Does pharmacogenomics provide an ethical challenge to the utilisation of cost-effectiveness analysis by public health systems?

Pharmacogenomics promotes an understanding of the genetic basis for differences in efficacy or toxicity of drugs in different individuals. Implementation of the outcomes of pharmacogenomic research into clinical practice presents a number of difficulties for healthcare. This paper aims to highlight one of the Unique ethical challenges which pharmacogenomics presents for the utilisation of cost-effectiveness analysis by public health systems. This paper contends that pharmacogenomics provides a challenge to fundamental principles which underlie most systems for deciding which drugs should be publicly subsidised. Pharmacogenomics brings into focus the conflict between equality and utility in the context of using cost-effectiveness analysis to aid distribution of a limited national drug budget.